Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- BAG1 BAG1S BAG1M BAG1L Bcl2 Raf1 cochaperone antiapoptotic posttranslational
- Product Overview:
Bcl-2-associated athanogene 1 (BAG-1) is a co-chaperone protein and member of the BAG family of proteins that has anti-apoptotic activity.{59746} It is composed of an N-terminal ubiquitin-like (UBL) domain and a conserved C-terminal BAG domain. BAG-1 has four isoforms, with the short (BAG-1S), medium (BAG-1M), long (BAG-1L) isoforms generated via alternative translation initiation sites and a BAG-1 isoform generated by post-translational modification.{59747} BAG-1L contains a nuclear localization signal in addition to the UBL and BAG domains and is the only isoform not found primarily in the cytoplasm.{59746} All BAG-1 isoforms are expressed ubiquitously and interact the anti-apoptotic protein Bcl-2 to increase its activity.{59747,59746} Under cell stress conditions, BAG-1 binds to the ATPase domain of Hsc70 or Hsp70 with its BAG domain and inhibits DNA synthesis and cell cycling. BAG-1 interacts with additional signaling proteins, including Raf-1, which activates ERK signaling and induces cell proliferation.{59746} Protein levels of BAG-1 are increased in patient-derived invasive breast carcinoma tissue but, in contrast, its expression is positively associated with increased survival in early-stage breast cancer patients.{59748,59749} Cayman’s BAG-1 Rabbit Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes the short, medium, and long isoforms of BAG-1 from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.